Foundation
Laboratorios Concordia was founded in May 1998 to distribute, market, and promote high-quality pharmaceutical products at competitive prices.
First Alliances
The first promotion and co-promotion contracts are signed with Mayoly Spindler (France) and Sanofi-Aventis (France).
New partnerships
Laboratorios Concordia partners with Biocodex (France), Gerolymatos (Greece), and Zambon (Italy).
Launches
Sinomarin, Lysomucil, and a fosfomycin trometamol product are launched to the market.
New partners
New alliances are formed with Protina (Germany) and Diprogen (Mexico) to expand the product portfolio with:
- Diasporal 300mg
- A mometasone furoate nasal spray
- A line of oral corticosteroids
Post-pandemic
After the pandemic, Laboratorios Concordia enters a new era, partnering with Gynov (France) to bring G-Nositol to the Mexican market. At the same time, the Diasporal line is expanded with the introduction of the 400mg presentation. For the second half of 2024, the portfolio grows with Orrei and a platelet aggregation inhibitor.
Our integrated process ensures the successful launch of products in the Mexican market. To achieve this, we follow these steps:

We conduct thorough research to assess the product's potential and determine if the environment is favorable. If the opportunity is viable, we begin the process of obtaining the necessary health registration or documentation for product importation. The logistics of the product importation are carefully evaluated, ensuring compliance with all requirements to optimize transportation and storage. The commercial process begins once the first import has arrived at the warehouse, passed the necessary analyses, and the product has been released for commercialization. The next step is to initiate promotion with the Honorable Medical Corps through the commercial teams.